Medicine Grand Rounds - Immune-Related Toxicities with Immune Checkpoint Inhibitors
Offered By: Dartmouth College via Independent
Course Description
Overview
Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Immune-Related Toxicities with Immune Checkpoint Inhibitors, 12/17/2021 8:00:00 AM - 12/17/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Keisuke Shirai, MD
Associate Professor of Medicine
Geisel School of Medicine at Dartmouth
Director of Melanoma Program, Section of Medical Oncology
Dartmouth-Hitchcock Medical Center
About our Presenter
Dr. Keisuke Shirai is a graduate of Kyoto University, Faculty of Medicine, Japan, completed his residency in Internal Medicine at University of Pittsburgh and Hematology Oncology fellowship at the Medical University of South Carolina. He then served on the faculty at the Medical University of South Carolina. He was recruited to Dartmouth Hitchcock as Director of the Melanoma Program. He was recently selected as a member of the melanoma immunotherapy guideline expert panel at the Society for Immunotherapy of Cancer.
Learning Outcome(s)
Participants will be able to review common irAEs (immune related adverse effects) and rare but serious irAEs of checkpoint inhibitors, and the importance of a team approach for the standard and unique management of these complications.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Keisuke Shirai, MD
Associate Professor of Medicine
Geisel School of Medicine at Dartmouth
Director of Melanoma Program, Section of Medical Oncology
Dartmouth-Hitchcock Medical Center
About our Presenter
Dr. Keisuke Shirai is a graduate of Kyoto University, Faculty of Medicine, Japan, completed his residency in Internal Medicine at University of Pittsburgh and Hematology Oncology fellowship at the Medical University of South Carolina. He then served on the faculty at the Medical University of South Carolina. He was recruited to Dartmouth Hitchcock as Director of the Melanoma Program. He was recently selected as a member of the melanoma immunotherapy guideline expert panel at the Society for Immunotherapy of Cancer.
Learning Outcome(s)
Participants will be able to review common irAEs (immune related adverse effects) and rare but serious irAEs of checkpoint inhibitors, and the importance of a team approach for the standard and unique management of these complications.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Tags
Related Courses
80028094 - Adolescent and Young Adult (AYA) Oncology Peter Shaw, MDJohns Hopkins University via Independent 80028094 - JHACH On-Demand CME 32522: Physical Activity in Pediatric Oncology Patients Jennifer Dean, MD
Johns Hopkins University via Independent Bone Tumor Case 2
Stanford University via Independent Medical Terminology II
City College of San Francisco via California Community Colleges System Children's Week: Considerations in Pediatric Oncology: Fertility Preservation and Managing Menses (RECORDED SESSION)
Stanford University via Independent